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The pentaspan membrane glycoprotein CD133
marks lineage-specific cancer progenitor cells and
is associated with poor prognosis in a number of
tumor types. Despite its utility as a cancer progenitor
cell marker, CD133 protein regulation and molecular
function remain poorly understood. We find that
the deacetylase HDAC6 physically associates with
CD133 to negatively regulate CD133 trafficking
down the endosomal-lysosomal pathway for degra-
dation. We further demonstrate that CD133,
HDAC6, and the central molecule of the canonical
Wnt signaling pathway, b-catenin, can physically
associate as a ternary complex. This association
stabilizes b-catenin via HDAC6 deacetylase activity,
which leads to activation of b-catenin signaling
targets. Downregulation of either CD133 or HDAC6
results in increased b-catenin acetylation and degra-
dation, which correlates with decreased proliferation
in vitro and tumor xenograft growth in vivo. Given
that CD133 marks progenitor cells in a wide range
of cancers, targeting CD133 may be a means to treat
multiple cancer types.
INTRODUCTION
The CD133 (prominin-1) epitope AC133 has been associated
with cancer progenitor cells in brain, colon, pancreas, liver,
lung, skin, prostate, and ovarian cancers (Ferrandina et al.,
2009). AC133 was first discovered as a marker of CD34+ human
hematopoietic progenitors (Yin et al., 1997). Characterization of
AC133 found it to be specific to CD133, a 120 kDa pentaspan
transmembrane protein (Miraglia et al., 1997), which has eight
predicted N-glycosylation sites on its two extracellular loopsC(Yin et al., 1997). CD133 is primarily localized to plasma
membrane protrusions (Corbeil et al., 2000; Weigmann et al.,
1997), where it can bind to cholesterol and associate with
membrane microdomains (Ro¨per et al., 2000). Importantly,
cancer cells marked by AC133 are thought to be more resistant
to traditional cancer treatments, including some chemotherapies
and radiotherapy, and thismay explain some instances of cancer
relapse (Ferrandina et al., 2009).
Insights into CD133 function come from the discovery of a
single-nucleotide frameshift mutation in the CD133 gene, which
leads to autosomal-recessive retinal degenerative disease (Maw
et al., 2000). Consistent with these observations, the CD133
knockout mouse displays retinal degeneration leading to blind-
ness (Zacchigna et al., 2009). Together, these observations
establish a physiological role for CD133 in proper retinal devel-
opment; however, it does not address its functional significance
in cancer.
This study presents evidence for physical interactions
between CD133, the deacetylase HDAC6, and b-catenin, the
central regulator of canonical Wnt signaling. We demonstrate
that HDAC6 governs CD133 trafficking into the endosomal-lyso-
somal degradation pathway. Moreover, decreasing CD133
levels or HDAC6 activity correlates with expression of mesen-
chymal-to-epithelial differentiation markers in colon and ovarian
cancer cell lines. Our results show that CD133 is important for
cell proliferation and anchorage-independent growth in vitro
and tumor xenograft growth in vivo. Finally, we present a model
whereby CD133, HDAC6, and b-catenin form a ternary complex
to contextually stabilize b-catenin through HDAC6 deacetylase
activity.
RESULTS
CD133 Physically Associates with HDAC6
To identify a function for CD133, we employed the mammalian
affinity purification and lentiviral expression (MAPLE) sys-
tem coupled to liquid chromatography and tandem massell Reports 2, 951–963, October 25, 2012 ª2012 The Authors 951
spectrometry (LC/MS) (Mak et al., 2010) to uncover CD133-
associated protein interaction partners. We previously gener-
ated a human embryonic kidney (HEK) 293 cell line that stably
expresses CD133 with a C-terminal versatile affinity (VA) tag
(hereafter referred to as HEK293/CD133-VA cells) (Mak et al.,
2011). HEK293/CD133-VA lysates were subjected to a single
round of Flag purification, and the purified proteins were subse-
quently analyzed by LC/MS. After using strict selection criteria to
determine protein hits with high confidence (see Experimental
Procedures), HDAC6 emerged as the only candidate interaction
partner for CD133 (Table S1). Unlike other histone deacetylases,
HDAC6 is primarily cytoplasmic, associated with microtubules
and dynein motors, and directly regulates the acetylation state
of a-tubulin at lysine 40 through its deacetylase activity (Hubbert
et al., 2002; Zhang et al., 2003, 2006).
The CD133-HDAC6 physical interaction was confirmed by
coimmunoprecipitation (co-IP) followed by western blotting in
HEK293 cells (data not shown) and Caco-2 cells (Figure 1A) en-
gineered to express VA-tagged CD133. To further validate the
interaction between CD133 and HDAC6, we performed endoge-
nous co-IPs with cell lysates from unmodified Caco-2 cells and
found that HDAC6 could specifically be pulled down with immu-
noprecipitated CD133 protein (Figure S1A). To map the residues
in CD133 that are important for its interaction with HDAC6, we
created CD133 truncation mutants and generated a series of
Caco-2 cell lines stably expressing these constructs. We found
that a truncation mutant that contained the first intracellular
region of CD133 (CD133(1–445)) maintained binding to HDAC6,
whereas a truncation mutant lacking the part of the first intracel-
lular region of CD133 (CD133(1–132)) had significantly reduced
binding to HDAC6 (Figure 1B). Therefore, we suggest that the
first intracellular region of CD133 is required for its interaction
with HDAC6.
As additional evidence of the CD133-HDAC6 interaction in
Caco-2 cells, we confirmed that endogenous HDAC6 protein
could specifically immunoprecipitate CD133 from Caco-2 cell
lysates (Figure S1A). To map the HDAC6 region that interacted
with CD133, we generated a series of HDAC6 mutants and sta-
bly introduced them into Caco-2 cells by using the MAPLE
system described above. A wild-type, deacetylase-deficient
(DD), and a BUZ-domain-deficient HDAC6 interacted with
endogenous CD133, as well as a truncated form of HDAC6 con-
taining both catalytic domains (1–840 amino acids [AA]) (Fig-
ure 1C, lanes 2–5). In contrast, a truncation mutant of HDAC6
that only contained the first catalytic domain of HDAC6 (1–503
AA) had reduced binding to endogenous CD133 (Figure 1C,
lane 6). These findings suggest that the second HDAC6 catalytic
domain (504–840) is required to bind CD133 in its first intracel-
lular loop.
Interestingly, HDAC6 protein regulation occurs through
phosphorylation of S568 and/or Y570, which leads to inhibition
of the deacetylase activity of HDAC6 (Deribe et al., 2009).
Given that S568 and Y570 reside within the second HDAC6
catalytic domain, we hypothesized that CD133 binds this region
of HDAC6 to competitively inhibit HDAC6 phosphorylation
and, hence, deactivation. Indeed, phospho-mimicking HDAC6
mutants S568E or Y570E were unable to immunoprecipitate
endogenous CD133 in Caco-2 cells, whereas the wild-type952 Cell Reports 2, 951–963, October 25, 2012 ª2012 The AuthorsHDAC6 or phospho-null HDAC6 mutants S568A and Y570F
could (Figure 1D).
To further validate the CD133-HDAC6 interaction by using
an independent approach, we used the membrane yeast two-
hybrid (MYTH) assay (Gisler et al., 2008; Snider et al., 2010). In
the event of a protein-protein interaction, the MYTH assay relies
on the cleavage of a reconstituted split ubiquitin moiety by an
endogenous yeast protease, resulting in the release of the
LexA transcription factor (TF) for ADE2/HIS3/b-galactosidase
reporter activation (Gisler et al., 2008). Expression of CD133 in
the MYTH system, where the signal sequence of the a-mating
pheromone precursor (MFa) is fused to the C-terminal ubiquitin
(Cub) fragment, which is in turn fused to the LexA(VP-16) tran-
scription factor (MFa-CD133-C-T), was confirmed by western
blot analyses in the MYTH reporter yeast strain THY.AP4 (Fig-
ure S1B). MFa-CD133-C-T was properly integrated into yeast
membrane compartments as determined by N-terminal ubiquitin
(Nub) I13G/NubI controls (Gisler et al., 2008) (Figures 1E and
S1C). Expression of the MFa-CD133-C-T bait and the NubG-
fused HDAC6 prey resulted in activation of the MYTH reporter
in THY.AP4 cells (Figure 1E). CD133-C-T interacted specifically
with HDAC6 as it did not interact with another histone deacety-
lase, HDAC10 (Figure S1C). Furthermore, two negative control
baits, MFa-CD4 transmembrane (TM)-C-T or MFa-SLC22A1-
C-T, did not activate the MYTH reporter when expressed with
NubG-HDAC6 (Figures 1E and S1D). Overall, our data indicate
that CD133 and HDAC6 can physically associate by using
multiple protein interaction assays.
HDAC6 Negatively Regulates CD133 Trafficking
into the Endosomal-Lysosomal Pathway
Based on the recent reports demonstrating that HDAC6 regu-
lates EGFR stability (Deribe et al., 2009; Gao et al., 2010), we
hypothesized that HDAC6 may also regulate the stability of
CD133. To examine this idea, we stably knocked down HDAC6
by using lentiviral-based short hairpin RNA (shRNA) (Moffat
et al., 2006) in cell lines that endogenously express CD133 (Fig-
ure 2A). HDAC6 knockdown resulted in a dramatic reduction of
CD133 protein in the colon adenocarcinoma cell lines Caco-2
and HT-29, a retinoblastoma cell line Weri-Rb-1, an ovarian
serous adenocarcinoma cell line OVCAR-8 (Figures 2A and
S2A), and an acute lymphoblastic leukemia cell line SEM-K2
(Figure S4A).
Given that HDAC6 was first identified to deacetylate a-tubulin,
we monitored acetylated a-tubulin levels to demonstrate that
our HDAC6 knockdown was sufficient to affect its functional
impact. As expected, the decrease in HDAC6 transcript levels
by knockdown with two independent shRNAs correlated with
an increase in acetylated a-tubulin (Figure 2A). By contrast, no
change in HDAC6 protein or transcript levels was observed
with CD133 knockdown by using two independent shRNAs
targeting CD133 (Figures 2B and 6C). Given that HDAC6 can
participate in regulating gene transcription, we investigated
the impact of HDAC6 knockdown on CD133 transcript levels.
We did not observe any significant differences in CD133
transcript in the presence of HDAC6 knockdown (Figure 2B),
suggesting that HDAC6 exerts its regulatory activity on CD133
at the protein level.
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Figure 1. CD133 Interacts with HDAC6
(A) Whole-cell lysates (input) and IPs of VA-tagged CD133 or GFP from engineered Caco-2 cells followed by anti-Flag and anti-HDAC6 western blots.
(B) Whole-cell extracts (input) from Caco-2 cell lines stably expressing the CD133-VA truncations 1–132 AA or 1–445 AA were used in anti-Flag IPs followed by
western analysis using anti-Flag and anti-HDAC6 antibodies.
(C) Lysates fromCaco-2 cell lines stably expressing either VA-HDAC6-WT, VA-HDAC6-DD, VA-HDAC truncations (1–503, 1–840,DBUZ), or VA-GFPwere used in
anti-Flag IPs followed by western analyses using anti-Flag and anti-AC133 antibodies.
(D) Lysates fromCaco-2 cells (untransduced) or Caco-2 cell lines stably expressing wild-typeHDAC6 or a specificHDAC6 pointmutant (S568E, S568A, Y570E, or
Y570F) were used in anti-Flag IPs and analyzed by western blot for interaction with endogenous CD133 using anti-AC133 antibodies.
(E) MFa-CD133-C-T or the control MFa-CD4(TM)-C-T were expressed in the yeast strain THY.AP4 along with NubG-HDAC6 and assayed for growth on selective
media. MFa-CD133-C-T was also expressed in THY.AP4 along with positive controls Ost1-NubI and Fur4-NubI and the negative controls Ost1-NubG and
Fur4-NubG to demonstrate absence of self-activation and proper membrane integration.
See also Figure S1.To investigate whether the deacetylase activity of HDAC6 was
responsible for the downregulation of CD133 and to provide
chemical genetic evidence for our observations, we used the
small molecule trichostatin A (TSA), which is an inhibitor ofCclass I and class II HDACs, including HDAC6. Consistent with
the HDAC6 knockdown data described above, we observed
a noticeable decrease in CD133 protein levels by western blot
analysis (Figure S2B) but no significant difference in CD133ell Reports 2, 951–963, October 25, 2012 ª2012 The Authors 953
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Figure 2. HDAC6 Negatively Regulates CD133 Trafficking Endosomes via Its Deacetylase Activity
(A) Caco-2, HT-29, Weri-Rb-1, and OVCAR-8 cancer cell lines were transduced with two independent shRNAs targeting HDAC6 or a control shRNA targeting
LacZ, and target knockdown was determined by western blot analyses using anti-HDAC6 antibodies. CD133, acetylated tubulin, and tubulin levels were all
monitored by western blot.
(B) Quantitative RT-PCR for HDAC6 and CD133 mRNA expression following knockdown of HDAC6 or CD133 using two independent shRNAs targeting each
transcript. Error bars represent SD (n = 3).
(C) Cancer cell lines described in (A) and (B) were treated with either vehicle only (DMSO), the HDAC6-specific inhibitor tubacin, or its inactive
counterpart niltubacin at 100 mM for Caco-2 and 20 mM for the remaining cell lines for a duration of 24 hr. Western blot analyses were performed as described
in (A).
(D) MFa-CD133-C-T or the control MFa-CD4(TM)-C-T were expressed in the yeast strain THY.AP4 along with NubG-CD63 and assayed for growth on
selective media.
(E) AC133 and CD63 immunofluorescence of Caco-2 cells treated with tubacin or niltubacin, as described above, were imaged by confocal microscopy. Nuclei
were stained with Hoechst 33342. Scale bar, 50 mm.
(F) Number of cells with a CD133-CD63 colocalization pattern as seen in (E) were counted by eye from a minimum of 200 cells treated with either tubacin or
niltubacin. Error bars represent SD (n = 3). *p < 0.05 as determined by a Student’s t test.
See also Figures S2 and S3.transcript (Figure S2C; p > 0.05) following TSA treatment. To
demonstrate that the effects of TSA were specifically due to
its inhibition of HDAC6, we used the HDAC6-specific small-
molecule inhibitor tubacin, as well as its inactive counterpart
niltubacin as a control (Haggarty et al., 2003). Treatment of
Caco-2, HT-29, Weri-Rb-1, OVCAR-8, or SEM-K2 cells with
tubacin resulted in a decrease in CD133 (Figures 2C and S4B),954 Cell Reports 2, 951–963, October 25, 2012 ª2012 The Authorsbut not HDAC6, protein levels, compared to treatment with niltu-
bacin or vehicle alone (Figure 2C). Similar to shRNA-mediated
knockdown of HDAC6, tubacin treatment did not have a statisti-
cally significant (p > 0.05) effect on CD133 transcript levels rela-
tive to cells treated with niltubacin (Figure S2D).
In contrast to inhibition of HDAC6 activity, overexpression of
wild-type HDAC6 in Caco-2 cells by the MAPLE system
(Figure S2E) or into HT-29 cells by transient transfection (Fig-
ure S2F) led to a slight increase in endogenous CD133 levels,
whereas overexpression of HDAC6-DD was comparable to
expression of green fluorescent protein (GFP). Together, our
results are consistent with amodel whereby HDAC6 deacetylase
activity is required for the stabilization of CD133 protein in cell
lines from multiple cancer types.
To further support our RNA interference (RNAi) knockdownand
small-molecule inhibition of HDAC6, we observed a destabiliza-
tion of total CD133 protein, but not transcript, levels in Caco-2
cells when the lysine residue positioned at amino acid 129 in the
first intracellular loop of CD133 was mutated to an alanine (Fig-
ures S2G and S2H). Given our model and supporting data that
HDAC6 binds to the first intracellular loop of CD133 and that its
deacetylase activity is required for CD133 stability, we suggest
that the K129A mutation may block the interaction between
CD133 and HDAC6, leading to CD133 degradation. Notably, we
were only able to detect lysine acetylation on CD133 by mass
spectrometry on lysines predicted to reside extracellularly
(A.B.M., M. Pehar, L. Puglielli, and J.M., unpublished data).
In an effort to elucidate the mechanism of CD133 turnover, we
treated Caco-2 cells with the proteasome inhibitor MG132 but
observed no significant changes in CD133 protein expression
levels (Figure S3A). Moreover, inhibition of proteasome activity
by MG132 treatment did not rescue expression of CD133 in
Caco-2 cells depleted of HDAC6 activity using shRNAs targeting
HDAC6 or the small-molecule inhibitor tubacin (Figures S3B and
S3C). These results suggest that CD133 downregulation is not
through proteasomal degradation.
In parallel to our MS studies to identify putative CD133-inter-
acting proteins, we also performed a CD133 MYTH screen
against a complementary DNA (cDNA) library isolated from adult
human kidney to identify CD133 interaction partners (Table S2).
Notably, the endosomal- and lysosomal-associated marker
CD63 was found to interact with CD133 (Figure 2D). Given that
CD63 is an endosomal marker, we hypothesized that CD133
degradation may occur through an endocytic cycle. Removal
of HDAC6 activity resulted in loss of CD133 expression at the
plasma membrane and a strong colocalization with CD63 in
Caco-2 cells (Figures 2E, 2F, and S3D). Moreover, we observed
that CD133 protein levels persist in the presence of the endoso-
mal-lysosomal pathway inhibitor ammonium chloride following
inhibition of HDAC6 activity by shRNA-mediated knockdown
(Figure S3B) or the small-molecule inhibitor tubacin (Figure S3C).
To further investigate whether trafficking of CD133 into the endo-
somal-lysosomal pathway required CD63, we knocked down
CD63 with two independent shRNAs and observed no change
in CD133 stability (Figures S3F and S3G). Furthermore, CD63
knockdowns did not impair the downregulation of CD133
when Caco-2 cells were treated with tubacin (data not shown).
Together, these observations are consistent with the model
that HDAC6 regulates CD133 stability through the endosomal-
lysosomal pathway.
CD133 Potentiates Cancer Cell Proliferation
and Tumorigenesis
In contrast to a previous report showing that siRNA-mediated
knockdown of CD133 elicited no effect on the proliferation ofCCaco-2 cells (Horst et al., 2009), we found that knocking down
CD133 by shRNAs in multiple cell lines, including Caco-2 and
OVCAR-8 cells, significantly reduced proliferation (Figure 3A;
p < 0.05). Notably, knockdown of HDAC6 also significantly
reduced proliferation of Caco-2 and OVCAR-8 cells (Figure 3A;
p < 0.05). The reduced proliferation observed in Caco-2 and
OVCAR-8 cells following knockdown of CD133 or HDAC6 was
due to a reduction in clonogenicity (Figure 3B).
To extend the idea that CD133 and HDAC6 may be collabo-
rating to promote cell proliferation, we assessed the ability of
CD133- and HDAC6-depleted cells to grow in an anchorage-
independent fashion in soft agar colony forming assays and
observed a significant reduction in the number of colonies rela-
tive to control cells (Figure 3C; p < 0.05). As anchorage-indepen-
dent growth is a well-known hallmark of cancer, we investigated
the impact of CD133 and HDAC6 depletion on tumor growth by
subcutaneously implanting OVCAR-8 cells stably expressing a
control shRNA or shRNAs targeting CD133 or HDAC6 into
NOD/SCID/IL2Rg/ (NSG) mice and observed no significant
difference in tumor size between uninfected and control infected
OVCAR-8 cells (Figure S4C; p = 0.43). Notably, OVCAR-8 tumors
with stable knockdown of either CD133 or HDAC6 were signifi-
cantly smaller than control tumors (Figure 3D; p < 0.001).
Together, these data indicate that CD133 and HDAC6 each
promote proliferation in some cancer cell lines.
Consistent with a previous study in the FEMX-I melanoma cell
line (Rappa et al., 2008), we found that CD133 is required for the
survival of SEM-K2 cells (Mak et al., 2012). Consistent with the
idea that HDAC6 is stabilizing CD133 levels, inhibition of
HDAC6 activity by shRNA knockdown or tubacin treatment
also resulted in significant apoptosis in SEM-K2 as measured
by Annexin V staining (Figures S4A and S4B). Despite these
findings, there is controversy surrounding howCD133 influences
cell proliferation, as others have found that CD133 expression
suppresses differentiation in a subset of neuroblastoma cell
lines (Takenobu et al., 2011). Given these discrepancies, we
next set out to determine the mechanism by which CD133
and HDAC6 promote proliferation in certain colon and ovarian
cancer cell lines.
CD133 Suppresses Cancer Cell Differentiation
and Mesenchymal-to-Epithelial Transition
Consistent with previous reports (Elsaba et al., 2010), apoptosis
was not evident in Caco-2 cells after CD133 knockdown (data
not shown). Therefore, we examined a panel of differentiation
markers in Caco-2 cells to determine whether CD133 was
functioning to suppress cell differentiation and found that upre-
gulation of genes associated with epithelial differentiation
(CK20, MUC2, and FABP2) (Figure 4A; p < 0.05), as well as
activity of the enterocytic differentiation marker alkaline phos-
phatase (Figure 4B; p < 0.01), correlated with knockdowns of
CD133 or HDAC6 in Caco-2 cells. Further analyses revealed
upregulation of genes involved in colon-specific differentiation
(Table S3). Loss of CD133 in OVCAR-8 cells leads to changes
in differentiation markers as evidenced by loss of the high-
mobility group AT-hook 2 (HMGA2) oncogene (Figure 4C;
p < 0.01), a marker of poorly differentiated, advanced cancers
(Shell et al., 2007).ell Reports 2, 951–963, October 25, 2012 ª2012 The Authors 955
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Figure 3. CD133 Promotes Cell Proliferation and Tumorigenesis
(A) Cell number relative to day 0 for Caco-2 and OVCAR-8 cells treated with control, CD133, or HDAC6 shRNAs. Error bars represent SD (n = 3).
(B) Clonogenic assay of Caco-2 and OVCAR-8 cells treated with control, CD133, or HDAC6 shRNAs. Error bars represent SD (n = 3).
(C) Soft agar colony forming assay to measure anchorage-independent growth of Caco-2 and OVCAR-8 cells treated with control, CD133, or HDAC6 shRNAs.
Error bars represent SD (n = 3). *p < 0.05 and #p < 0.01 as determined by a Student’s t test.
(D) Tumor volume 40 days after 53 105 shRNA-treated OVCAR-8 cells were subcutaneously implanted in NOD/SCID/IL2Rg/mice. Errors bars represent SEM
(n = 10). ***p < 0.001 as determined by analysis of variance (ANOVA).
See also Figure S4.HMGA2 was demonstrated to be a prognostic marker for
ovarian cancer alongside classical markers associated with
epithelial-mesenchymal transition (EMT), E-cadherin (CDH1),
and vimentin (VIM) (Shell et al., 2007). In OVCAR-8 cells, down-
regulation of CD133 resulted in an increase of the epithelial
marker E-cadherin (CDH1) and a decrease of the mesenchymal
markers N-cadherin (CDH2) and vimentin (VIM) (Figures 4D and
S5A). Furthermore, significant reduction of the EMT transcription
factor program was observed by quantitative PCR, including
downregulation of ZEB2, TWIST, SNAIL, and SLUG (Figure 4E;
p < 0.05), suggesting that loss of CD133 in OVCAR-8 cells
promotes a mesenchymal-to-epithelial transition (MET). This
transition was further observed with epithelial-like morphological
changes and the reduction of mesenchymal-associated stress956 Cell Reports 2, 951–963, October 25, 2012 ª2012 The Authorsfibers (Figure S5B). Therefore, downregulation of CD133 expres-
sion through the deacetylase activity of HDAC6 is a trigger for
differentiation.
As it has been established that EMT is involved in migration
and invasion in cancer metastasis (Thiery et al., 2009), we inves-
tigated the impact of CD133 and HDAC6 in migration and in cell
invasion in OVCAR-8 cells and observed a significant decrease
in their ability to invade basement membrane extract relative to
control (Figure 4F; p < 0.05). In further support of decreased
cell invasion in OVCAR-8 cells depleted for CD133 or HDAC6,
we observed a reduction in expression of mesenchymal- and
metastasis-associated genes, including SLUG, LAMC1, and
MMP7 (Figure 4E). Interestingly, these genes are reported
targets of the Wnt/b-catenin signaling pathway (Brabletz et al.,
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Figure 4. CD133 Suppresses Cancer Cell Differentiation
(A) Relative transcript levels of epithelial differentiation markers CK20, MUC2, and FABP2 asmeasured by quantitative PCR of shRNA-treated Caco-2 cells. Error
bars represent SD (n = 3).
(B) Activity of the enterocytic marker alkaline phosphatase (AP) following knockdown of HDAC6 or CD133 in Caco-2 cells. Error bars represent SD (n = 4).
(C) Relative transcript levels of the ovarian differentiationmarker HMGA2 asmeasured by quantitative PCR of shRNA-treatedOVCAR-8 cells. Error bars represent
SD (n = 3).
(D) Western blot analyses for epithelial (E-cadherin) and mesenchymal (N-cadherin and vimentin) markers in OVCAR-8 cells where CD133 or HDAC6 has been
knocked down with two independent shRNAs. CD133 and HDAC6 knockdowns are shown in Figure 4D. GAPDH immunoblots served as a loading control.
(E) QuantitativePCRofEMT-associatedandWnt signaling target genes following knockdownofCD133orHDAC6 inOVCAR-8cells. Error bars representSD (n=3).
(F) Invasion of basement membrane extract (BME) of OVCAR-8 cells (24 hr assay) treated with shRNAs to knock down CD133 or HDAC6. Cell invasion values are
relative to cell invasion of OVCAR-8 cells treated with the control shRNA targeting a nonhuman transcript, LacZ. Error bars represent SD (n = 3). *p < 0.05 and
#p < 0.01 as determined by a Student’s t test.
See also Figure S5.2009), raising the possibility that CD133 is directly involved in
promoting Wnt/b-catenin signaling.
CD133 Expression Promotes b-Catenin Signaling
in Colon and Ovarian Cancer Cells
To test whether Wnt/b-catenin signaling was active in Caco-2
and OVCAR-8 cells and whether CD133 is important for main-
taining a b-catenin signaling circuit, we carried out two sets of
experiments. First, we treated these cells with small mole-
cules—IWP-2 and IWR-1—that target the canonical Wnt
pathway (Chen et al., 2009). The effects of IWP-2 and IWR-1
on Caco-2 and OVCAR-8 cells were confirmed as the bona
fide TCF/LEF target AXIN2 was significantly decreased (Fig-
ure 5A; p < 0.05). IWP-2 or IWR-1 treatment of Caco-2 cells
also caused an upregulation of the differentiation markers
MUC2 and FABP2, whereas treatment of OVCAR-8 cellsCresponds by downregulating the mesenchymal markers
HMGA2 and VIM (Figure 5A; p < 0.05). Second, we used the
TOP-destabilized GFP (dGFP) b-catenin signaling reporter and
the control FOP-dGFP (Reya et al., 2003) to assess CD133
involvement in the b-catenin signaling. A significant decrease
of TOP-dGFP, but not FOP-dGFP, reporter expression in
Caco-2 and OVCAR-8 cells was observed with the loss of
CD133 (Figure 5B; p < 0.05). In addition, Wnt/ b-catenin signaling
negative feedback targets TCF-1, LEF-1, Axin2, and NKD1 were
also significantly decreased (Figure 5C; p < 0.05).
CD133 Stabilizes b-Catenin via HDAC6 Deacetylase
Activity
Because HDAC6 has previously been shown to associate with
b-catenin (Li et al., 2008), we performed endogenous co-IPs
with lysates from Caco-2 cells to determine whether CD133,ell Reports 2, 951–963, October 25, 2012 ª2012 The Authors 957
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Figure 5. CD133 Supports b-Catenin Signaling
(A) Quantitative PCR tomeasure transcript levels of differentiation markers for Caco-2 and OVCAR-8 cells treated for 24 hr with 5 mMof IWP-2 or 10 mMof IWR-1.
Cells treated with DMSO only acted as a control. Error bars represent SD (n = 3).
(B) Destabilized GFP (dGFP) transcript levels were measured by quantitative PCR for Caco-2 and OVCAR-8 cells stably expressing TOP- or FOP-dGFP treated
with shRNAs. Error bars represent SD (n = 3).
(C) Quantitative PCR was performed to measure Wnt signaling target genes in Caco-2 and OVCAR-8 cells treated with control, CD133, or HDAC6. Error bars
represent SD (n = 3). *p < 0.05 and #p < 0.01 as determined by a Student’s t test.HDAC6, and b-catenin could physically associate in a complex.
Indeed, IPs of endogenous CD133, HDAC6, and b-catenin
followed by western blotting demonstrated that these proteins
are capable of interacting at endogenous levels in Caco-2 cells
(Figures 6A and S1A). Interestingly, b-catenin appears to interact
exclusively with a lower-molecular-weight form of CD133, which
we (Mak et al., 2011) and others have previously identified as
a CD133 molecule that is N-glycosylated but lacks complex
N-glycosylation.
To further dissect the configuration of this complex, we used
the MYTH assay to test digenic interactions between each of
these proteins. The CD133-C-T bait and NubG-b-catenin did
not appear to interact by MYTH (data not shown and Figure 6B).
Therefore, we hypothesized that their association may be medi-
ated by HDAC6, and we introduced a vector encoding HDAC6
under a constitutive yeast promoter or an empty vector into the
system. Notably, expression of HDAC6 or the empty vector
alone in yeast cells did not influence the Ost1 NubG/NubI
controls. Also, NubG-b-catenin did not interact with the
CD4(TM)-C-T control bait in the presence or absence of
HDAC6 (Figure 6B). Consistent with the model that HDAC6
bridges the interaction between CD133 and b-catenin, expres-958 Cell Reports 2, 951–963, October 25, 2012 ª2012 The Authorssion of HDAC6, but not the empty vector, resulted in activation
of the MYTH reporter (Figure 6B), thus providing additional
evidence that CD133-C-T, HDAC6, and NubG-b-catenin physi-
cally associate in a complex. To visualize the localization of the
CD133-HDAC6-b-catenin complex in Caco-2 and OVCAR-8
cells, we performed immunofluorescence costaining experi-
ments and found a striking colocalization of CD133 and b-cate-
nin (Figure S6A; Pearson’s correlation = 0.82). By contrast, only
a small fraction of HDAC6 colocalized with CD133 and b-catenin
(Figure S6A).
We next monitored levels of b-catenin by western blot analysis
and observed a striking downregulation of total b-catenin protein
levels when CD133 or HDAC6 was each downregulated by two
independent shRNAs in Caco-2 or OVCAR-8 cells (Figure 6C)
and also from OVCAR-8 tumors generated in NSG mice (Fig-
ure S6B). Because HDAC6 has previously been shown to deace-
tylate b-catenin at lysine 49 to inhibit phosphorylation and
subsequent degradation (Li et al., 2008), we hypothesized
that CD133 regulated b-catenin via HDAC6. In support of this
and consistent with previous findings, the level of acetylated
b-catenin was increased when directly targeting CD133 or
when targeting HDAC6 (Figures 6C and S6B). Consistent with
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Figure 6. CD133 Stabilizes b-Catenin Expression
(A) Endogenous CD133 and b-catenin and control IgG were immunoprecipitated from Caco-2 lysates and analyzed by western blot for associated proteins,
including AC133, HDAC6, and b-catenin.
(B) MFa-CD133-C-T or the control MFa-CD4(TM)-C-T were expressed in the yeast strain THY.AP4 along with NubG- b-catenin, and either HDAC6 or empty
vector and yeast transformants were assayed for growth on selective media. MFa-CD133-C-T and either HDAC6 or empty vector were also expressed in
THY.AP4 along with positive controls Ost1-NubI and Fur4-NubI and the negative controls Ost1-NubG and Fur4-NubG to demonstrate absence of self-activation
and proper membrane integration.
(C) Caco-2 and OVCAR-8 cells infected with shRNAs targeting CD133 or HDAC6 and a panel of signaling events were analyzed by western blot, including
phospho-b-catenin (S33/S37/T41), acetylated b-catenin (K49), phospho-GSK3b, and acetylated a-tubulin, as well as CD133, HDAC6, b-catenin, GSK3b,
and a-tubulin.
See also Figure S6.a previous study (Li et al., 2008), this correlated with an increase
of phosphorylated b-catenin relative to total levels of b-catenin
(Figure 6C). However, in stark contrast to b-catenin levels, we
found no significant differences in the levels of total or phos-
pho-glycogen synthase kinase (GSK) 3-b (Figure 6C).
As stabilized b-catenin translocates to the nucleus to target
TCF/LEF target genes, we tracked b-catenin localization by
immunofluorescence and by immunohistochemistry in the pres-
ence and absence of CD133 and HDAC6. A striking decrease in
cytoplasmic and nuclear localized b-catenin was observed in
CD133 and HDAC6 knockdowns in vivo (Figure S6C) and
in vitro (Figure S6D). Given the above, we suggest that CD133Cregulates b-catenin acetylation via HDAC6 and, thus, its
phosphorylation, stability, and nuclear localization to influence
b-catenin signaling activity.
DISCUSSION
CD133 has been used as a molecular marker for stem cells
and cancer stem cells for more than a decade, yet its molecular
function has remained mysterious. Much work has been done to
link CD133-expressing cells to underlying molecular cancer
signatures and phenotypes with little insight into the posttransla-
tional regulation and molecular function of CD133. Our studyell Reports 2, 951–963, October 25, 2012 ª2012 The Authors 959
uncovers a protein-protein interaction between CD133 and
HDAC6, establishes a role for HDAC6 in CD133 turnover,
reveals a contextual role for CD133 and HDAC6 in the suppres-
sion of cancer cell differentiation and expression of Wnt target
genes, and directly links CD133, HDAC6, and b-catenin in
a protein complex. Together, these findings have broader
implications for regulation and turnover of multispanning cell
surface proteins and cell signaling through the canonical Wnt
pathway.
HDAC6 becomes phosphorylated at Y570 by EGFR following
activation by the EGF ligand (Deribe et al., 2009). This phosphor-
ylation event correlates with decreased HDAC6 deacetylase
activity, increased acetylation of K40 on a-tubulin, and increased
EGFR endocytosis (Deribe et al., 2009; Gao et al., 2010). We
explored the nature of the CD133-HDAC6 interaction by testing
whether HDAC6 phospho-mimicking mutants (Y570E and
S568E) could interact with CD133 and found that they could
not, whereas nonphosphorylatable HDAC6 mutants (Y570F
and S568A) still interacted with CD133. These results provide a
model to explore the signaling relationship between CD133
and HDAC6; for example, which kinase(s) and phosphatase(s)
regulate this interaction? Because phosphorylation of HDAC6
correlates with decreased HDAC6 deacetylase activity, we
propose that CD133 is not a substrate of HDAC6 but rather
promotes HDAC6 activity by protecting it from dephosphory-
lation. Our hypothesis is that this function creates a microenvi-
ronment for linking extracellular cues with cell surface features
that can communicate important signaling components like
b-catenin.
HDAC6 has previously been shown to be required for onco-
genic Ras- and ErbB2-induced transformation of fibroblast cells
and for anchorage-independent growth (Lee et al., 2008). These
results are consistent with our own finding that HDAC6 knock-
down results in decreased proliferation, colony formation, and
invasion in Caco-2 and OVCAR-8 cells as well as decreased
tumor growth in an OVCAR-8 xenograft model. Interestingly,
knockdown of CD133 had similar effects on proliferation,
anchorage independence, invasion, and xenograft growth in
Caco-2 and OVCAR-8 cells in our hands, raising the possibility
that CD133 and HDAC6 form a signaling module that positively
regulates cell state. These results are also consistent with
a recent report showing that CD133 knockdown caused
decreased proliferation and tumorigenic growth in the neuro-
blastoma cell line TGW (Takenobu et al., 2011) and decreased
anchorage-independent growth and colony formation in HT-29
cells (Elsaba et al., 2010). These findings are inconsistent with
previous observations showing that targeting CD133 in SEM-
K2 (Mak et al., 2012) or FEMX-I cells (Rappa et al., 2008) results
in apoptosis. Thus, the cellular role of CD133 appears to be
cancer cell type specific.
CD133 is associated with Wnt signaling in this study as well as
in an independent study examining the role of CD133 in FEMX-1
cells (Rappa et al., 2008), suggesting that cell-type-specific
responses to Wnt signaling activity may explain the differences
observed in the cellular role of CD133. Importantly, HDAC6
appears to be dispensable in the normal mouse physiology
and development (Zhang et al., 2008), as HDAC6 knockout
mice are viable and healthy and do not show any malignant960 Cell Reports 2, 951–963, October 25, 2012 ª2012 The Authorspredispositions. Similarly, CD133 is not essential for mouse
development or viability (Zacchigna et al., 2009). Together, these
results imply that HDAC6 and CD133 are required for cancer cell
proliferation—not normal cell proliferation—in certain cellular
contexts. The recent report showing that inhibition of HDAC6
induces DNA damage and sensitizes transformed cells to anti-
cancer agents raises the possibility that inhibition of CD133
may also sensitize transformed cells to anticancer agents (Nam-
dar et al., 2010).
Consistent with our findings, HDAC6 is required for transform-
ing growth-factor-b1-induced EMT through SMAD3-activating
HDAC6 deacetylation of a-tubulin (Shan et al., 2008). HDAC6
was also shown to increase cell motility via its interaction with
the F-actin binding protein cortactin (Zhang et al., 2007).
Previous observations demonstrate that CD133 primarily local-
izes to plasma membrane protrusions in migrating hematopoi-
etic progenitor cells, implying that CD133 also has a role in cell
migration (Giebel et al., 2004). Indeed, targeting CD133 in HT-
29 cells results in decreased cell migration (Elsaba et al.,
2010). In the present study, we extend these findings to
OVCAR-8 cells and show that CD133 and HDAC6 promote the
mesenchymal state, which is linked to motility and invasion.
These findings support a previous study that observed
decreased metastasis following depletion of CD133 by RNAi in
the melanoma cell line FEMX-I (Rappa et al., 2008). Together,
these observations suggest that CD133 and HDAC6 have
a role in promoting and maintaining a mesenchymal state, which
is associated with stem cell properties (Mani et al., 2008; Thiery
et al., 2009), and suggest that the CD133-HDAC6 signaling
module may have a role in establishing and maintaining such
properties in certain cancer cell contexts.
We relied on our identification of the CD133-HDAC6 interac-
tion and the previous report that demonstrated deacetylation
of lysine 49 of b-catenin by HDAC6 (Li et al., 2008) to identify
the CD133-HDAC6-b-catenin complex at the plasmamembrane
(Figure 7A). Knockdown of CD133 caused a dramatic increase in
acetylated b-catenin, but not acetylated a-tubulin (Figure 7B).
Given that HDAC6 is primarily localized to the cytoplasm, we
suggest that the HDAC6 activity responsible in deacetylating
a-tubulin and b-catenin is local to the minute fraction associated
with CD133 at the plasma membrane. We propose that the
molecular mechanism surrounding the role of CD133 in
b-catenin signaling is through the recruitment of HDAC6 to
deacetylate b-catenin for its stabilization and nuclear localiza-
tion. Total and phosphorylated GSK3b levels show no obvious
change when CD133 and HDAC6 are depleted from cells, sug-
gesting that CD133 regulation of b-catenin is via an independent
pathway of the upstream Wnt signaling pathway components
involved in GSK3b activity regulation.
Our results suggest that one mechanism by which CD133
governs cancer cell identity and state is through the b-catenin
signaling pathway (Figure 7). This is consistent with the finding
that the Wnt pathway is tightly linked to colon cancer and Wnt
signaling, and expression of AC133 is required for maintenance
of the colon cancer stem cell compartment (Vermeulen et al.,
2010). Furthermore, b-catenin is required for CD133+ leukemia
stem cells to drive acute myelogenous leukemia in mice (Wang
et al., 2010). Taken together, inhibiting CD133, HDAC6
Figure 7. Proposed Model Summary
(A) HDAC6 physically interacts with CD133 and
negatively regulates its trafficking into endosomes
by deacetylating a-tubulin. This allows for the
positive regulation of b-catenin signaling by
CD133 via recruitment of HDAC6 to deacetylate
b-catenin, resulting in its stabilization. Collectively,
this results in maintaining a primitive cancer cell
state.
(B) Inhibition of HDAC6 results in increased acet-
ylated tubulin, CD133 endocytosis, destabilization
of b-catenin, and, in some contexts, cancer cell
differentiation.deacetylase activity, or the b-catenin signaling pathway may be
a means to targeting certain cancer progenitor cells.
EXPERIMENTAL PROCEDURES
Affinity Purification and Mass Spectrometry Analysis
Cell extracts from HEK293/CD133-VA were incubated with Flag M2-agarose
beads (Sigma-Aldrich, Inc.) at 4C for 4 hr, followed by washing and elution
with 500 mM ammonium hydroxide (pH > 11). The eluate was lyophilized in
a SpeedVac and resuspended in 50 mM ammonium bicarbonate (pH 8–8.3)
with trypsin for 2 hr at 37C. The ammonium bicarbonate was removed by
SpeedVac, and the samples were suspended in 2% acetonitrile, 0.1% formic
acid. Samples were independently and directly loaded onto capillary columns
packed with Magic C18AQ (5 mm, 100 A˚). Data were acquired over a 2 hr
2%–40%acetonitrile gradient on a ThermoFinnigan LTQequippedwith a Prox-
eon NanoSource and an Agilent 1100 capillary pump. RAW files were con-
verted tomgf format andwere searchedwith theMascot search engine (Matrix
Sciences) against the human RefSeq database (release 24). To determine
specific interactions with high confidence, we filtered out hits also detected
in the control sample (i.e., HEK293/VA-GFP) as well as hits detected with
>20% frequency in the internal Samuel Lunenfeld Research Institute database
of human anti-Flag interactors. Only protein hits with a minimum of one unique
peptide and a MASCOT score greater than 60 and that were detected in all
biological replicates (n = 3) are reported.
Membrane Yeast Two-Hybrid Assay and Screen
MYTH analysis and screen were performed as previously described (Deribe
et al., 2009). Briefly, the MYTH screen for CD133 was performed by using
a cDNA library containing 2.6 3 106 independent clones. Approximately
83 106 transformants were screened by growth on selective media, and plas-
mids were isolated from 384 positive clones and retested in the MYTH system
for specificity toward CD133 versus the CD4(TM) control bait in independent
quadruplet (n = 4). Clones that were specific to CD133 were analyzed by
DNA sequencing and analyzed by bioinformatics to identify corresponding
gene hits. 25 unique gene hits from the MYTH screen were identified.
Proliferation and Clonogenic Assays
Total cell numbers were determined by a Z2 Coulter counter (Beckman
Coulter, Inc.) at indicated time intervals. Cell numbers were relative to the
number of cells plated per well at time 0, whichwas constant between samples
and replicates. For the clonogenic assay, single-cell suspensions of Caco-2
and OVCAR-8 stable lines were plated into 6-well plates at a density of
1,000 cells per well. After 2 weeks of culturing under conditions as described
above, cells were fixed in 4% paraformaldehyde in PBS for 15 min, stained
with 0.05% crystal violet for 15 min, and washed with water. Colonies visible
by eye and possessing >50 cells were counted.
Alkaline Phosphatase Assay
Alkaline phosphatase activity was determined by a fluorometric kit as per
manufacture’s protocol (ab83371, Abcam Inc.).CSoft Agar Colony Formation Assay
Approximately 1,000 Caco-2 or OVCAR-8 cells were resuspended in 0.5 ml of
0.35% Bacto agar (214050, BD, Sparks, MD) in the appropriate media and
plated on 0.5 ml of 0.5% Bacto agar bases that had settled for 30 min at
room temperature in 12-well plates. Appropriate liquid media were added to
each well and were changed weekly. The number of colonies was scored after
4 weeks of incubation for Caco-2 samples and after 2 weeks of incubation for
OVCAR-8 samples by staining with 0.005% crystal violet and counting by eye
under a dissection light microscope. Colonies possessing >50 cells were
counted.
Cell Invasion Assay
Cell invasion wasmeasured by using the Cultrex Basement Membrane Extract
cell invasion assay (3455-096-K, R&D Systems, Inc.) as per manufacture’s
protocol. A one-in-ten dilution of Basement Membrane Extract was used to
coat the inner-well chamber overnight, and OVCAR-8 stables were incubated
for 24 hr prior to quantitative measurements.
TOP/FOP Assays
Lentiviral constructs encoding the TOP-dGFP and FOP-dGFP reporters were
kindly provided by Dr. Laurie Ailles. Lentivirus was produced as described
above and used to stably transduce Caco-2 and OVCAR-8 cells at a
MOI >1. Stable cells were infected with shRNAs, and dGFP transcript was
measured by qRT-PCR.
Animals and Subcutaneous Xenografts
Eight-week-old female NOD/SCID/IL2Rg/ (NSG) mice were used and main-
tained according to Canadian Council of Animal Care (CCAC) guidelines.
Subcutaneous injection of 5 3 105 OVCAR-8 cells treated with or without
shRNAs into both hind flanks was performed. The inoculation volume was
40 ml in a 1:1 mixture of HBSS:Matrigel. Five mice (ten tumors total) per condi-
tion were used.
Plasmids and Antibodies
Primers and antibodies used in this study to generate plasmids, monitor tran-
script levels by quantitative RT-PCR, and perform western blots are described
in Tables S4, S5, and S6.
For a more detailed version of Experimental Procedures please see
Extended Experimental Procedures.
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